Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Start-Up Obsidian Gets $49.5m To Determine How And When To Activate CAR-T Cells

Dec 07 2017

• By Mandy Jackson

3d illustration of T cells or cancer cells

Related Content

Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah

Oct 19 2017

With Serial Entrepreneur At Its Helm, Arrakis Raises $38m To Target RNA With Small Molecules

Feb 27 2017

Value Unlocked: BMS Buying Padlock For Up To $600m

Mar 24 2016

Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

Aug 31 2017

Related Companies

Arrakis Therapeutics

Bristol Myers Squibb Company

Harvard University

ARIAD Pharmaceuticals, Inc.

Stanford University

Gilead Sciences, Inc.

Kite Pharma, Inc.

Roche Holding AG

Novartis AG

Additional Topics

Financing StartUps and SMEs ImmunoOncology Business Strategies Companies Commercial BioPharmaceutical

More from Financing

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.